pristiq compared to effexor
Although these events occurred during treatment with venlafaxine, causality has not pristiq compared to effexor determined.
A case of dose-related increase of intraocular pristiq compared to effexor caused by venlafaxine use has been reported.
Metabolic
Metabolic side effects have included weight loss (3%).
Metabolic side effects reported in premarketing Phase 3 trials have included weight gain, increased alkaline phosphatase, dehydration, hypercholesteremia, hyperglycemia, hyperlipemia, hypoglycemia, hypokalemia, increased SGOT (AST), increased SGPT (ALT), thirst, bilirubinemia, increased BUN, increased creatinine, diabetes mellitus, glycosuria, gout, abnormal healing, hemochromatosis, hypercalcinuria, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocholesteremia, hyponatremia, hypophosphatemia, hypoproteinemia, and uremia. Experience with the immediate-release venlafaxine showed that sustained hypertension was dose-related, increasing from 3% to 7% at 100 to 300 mg/day to 13% at doses above 300 mg/day. Experience with the immediate-release venlafaxine showed that sustained hypertension was dose-related, increasing from 3% to 7% at 100 to 300 mg/day to 13% at doses above 300 mg/day. There have been postmarketing reports of toxic epidermal necrolysis.
One case of venlafaxine-induced Stevens-Johnson syndrome has been reported. The reduction pristiq compared to effexor REM sleep is greatest early in treatment, but gradually returns towards baseline during long-term therapy; however, ROL remains long. In one case, toxic hepatitis associated with low dose (37.5 mg/day) venlafaxine was reported in a patient with a history of chronic hepatitis.
Endocrine
Endocrine side effects have included flushing.
Endocrine side effects reported in premarketing Phase 3 trials have rarely included galactorrhea, goiter, hyperthyroidism, hypothyroidism, thyroid nodule, and pristiq compared to effexor The authors state that it is possible that the anasarca was due to an allergic or delayed- type hypersensitivity reaction given the circumstances.
There are numerous case reports of withdrawal symptoms following abrupt discontinuation of treatment, and a single case report of severe tinnitus associated with venlafaxine.
Withdrawal effects occur upon abrupt discontinuation of treatment and the severity of symptoms appears to be dependent on length of therapy and dose (including low dose therapy). In a flexible-dose study, with doses in the range of 200 to 375 mg/day and mean dose pristiq compared to effexor than 300 mg/day, the mean pulse was increased by about 2 beats per minute compared with a decrease of about 1 beat per minute for placebo.
In controlled clinical trials, Effexor pristiq compared to effexor associated with mean increases in diastolic blood pressure ranging from 0.7 to 2.5 mm Hg averaged over all dose groups, compared to mean pristiq compared to effexor ranging from 0.9 to 3.8 mm Hg for placebo. The pristiq compared to effexor for including events was to enumerate those that occurred at an incidence of 5% or more for at least one of the venlafaxine groups and for which the incidence was at least twice the placebo incidence pristiq compared to effexor at least one Effexor group. Although these events pristiq compared to effexor during treatment with venlafaxine, causality has not been determined.
One case of anasarca was reported in a patient receiving venlafaxine. A case of increased libido and spontaneous erections has also been reported.
Although rare, several cases of venlafaxine- induced urinary symptoms including nocturia, enuresis, increased urge/frequency, and incontinence have been reported. Although these events occurred during treatment with venlafaxine, causality has not been determined.
There is a single case report of breast pain pristiq compared to effexor with venlafaxine therapy.
Dermatologic
At least 3 cases of venlafaxine- pristiq compared to effexor alopecia have been reported. Although these events occurred during treatment with venlafaxine, causality has not been determined.
Ocular
Ocular side effects have included abnormal vision, primarily blurred vision, in approximately 6% of patients. In addition, in premarketing assessment of Effexor XR (the pristiq compared to effexor release form of venlafaxine), multiple doses were administered to 705 patients in Phase 3 major depressive disorder studies and Effexor was administered to 96 patients. There have been postmarketing reports of toxic epidermal necrolysis.
One case of venlafaxine-induced Stevens-Johnson syndrome has been reported. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Tachycardia and QTc prolongation appear to occur in a dose-dependent manner.
In one case report, venlafaxine (75 mg 3 times/day) may have contributed to an elevation in defibrillation threshold in a patient with nonischemic cardiomyopathy and an implantable cardioverter- defibrillator. In addition, in premarketing assessment of Effexor XR (the extended release form of venlafaxine), multiple doses were administered to 705 patients in Phase 3 major depressive disorder pristiq compared to effexor and Effexor was administered to 96 patients. The rule for including events was to enumerate those that occurred at an incidence of 5% or more for at least one of the venlafaxine groups and for which the incidence was at least twice the placebo incidence for at least one Effexor group. Symptoms resolved following treatment with IV steroids and antidepressant therapy was pristiq compared to effexor switched to paroxetine.
Online pharmacy Tags
316 317 318 319 320 321 322 323 324
.